Kathryn E. Beckermann, MD, PhD, discusses the need for biomarkers in frontline renal cell carcinoma.
Kathryn E. Beckermann, MD, PhD, assistant professor of Medicine, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, discusses the need for biomarkers in frontline renal cell carcinoma (RCC).
There is not currently an actionable biomarker in this space, and identifying biomarkers for untreated patients with RCC will allow for more tailored therapies that could reduce financial toxicity, limit adverse effects (AEs), and provide the most clinical benefit, Beckermann explains. Beckermann and colleagues hope to start a clinical trial to examine if a patient’s therapy can be tailored based on their tumor profile.
Despite this need, there have still been great advances in RCC, Beckermann continues. When a patient first presents with RCC, it is important to consider how quick a response is needed and if a patient is symptomatic, Beckermann adds. These factors, plus comorbidities, play a role in determining what frontline treatment option patients should receive, Beckermann says.
It is also important to discuss a patient’s goals and advise them of any AEs associated with therapy options, which can help inform a joint decision on the best course of treatment, Beckermann concludes.